30 results about "Hepatic encephalopathy" patented technology

Provided is a Bifidobacterium lactis. The Bifidobacterium lactis is Bifidobacterium animalis subsp. lactis BL-11, and the preservation number of the Bifidobacterium animalis subsp. lactis BL-11 is CGMCC No. 20847. The provided Bifidobacterium animalis subsp. Lactis can improve intestine metabolism disorder and normalize the composition of intestine microbiome so as to improve height, suppresses obesity, promote infant and youth physical development and mental development, and prevent and treat mental disorders, said mental disorders including anxiety, depression, attention-deficit / hyperactivity disorder, autism, schizophrenia, hepatic encephalopathy, anorexia, Tourette syndrome, and Asperger syndrome.

The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and / or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation, as well as retinal edema), as well as hyponatremia and excess fluid retention, and diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and / or tissue hydration, myocardial ischemia, myocardial ischemia / reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines, as well as to novel assays for identifying aquaporin inhibitors.

Aspects of the disclosure relate to oligosaccharide compositions and methods of making the same. Also provided are methods of using oligosaccharide compositions as microbiome metabolic therapies for reducing ammonia levels and for the treatment of hyperammonemia-related diseases (e.g., urea cycle disorders and hepatic encephalopathy).

The invention relates to the field of biomedical application of inorganic materials, in particular to application of lanthanum carbonate in preparation of a medicine for treating hepatic encephalopathy. According to the application of lanthanum carbonate in preparation of the medicine for treating hepatic encephalopathy, the medicine comprises lanthanum carbonate and pharmaceutically acceptable auxiliary materials, the lanthanum carbonate comprises any one or more of lanthanum carbonate hydrate and basic lanthanum carbonate, the medicine is ground and then mixed with food to prepare a medicine mixture, and the medicine mixture is prepared into the medicine for treating hepatic encephalopathy. The mass ratio of the lanthanum carbonate in the medicine mixture is 1-10%. According to the application, the blood ammonia is reduced based on the glutaminase, the hepatic encephalopathy is reversed by reducing the blood ammonia and systemic inflammation, and the liver function is recovered by regulating the inflammation, so that the hepatic encephalopathy is favorably cured, a good treatment effect is shown, and a new candidate medicine is provided for clinically treating the hepatic encephalopathy.

The present disclosure provides freeze-dried and liquid compositions that include an extract of human feces. Also provided are methods for making and using such compositions, including methods for replacing or supplementing or modifying a subject's intestinal microbiota, and methods for treating a disease or condition such as hepatic encephalopathy.

The application discloses a kind of based on brain structure image's hepatic encephalopathy evaluation method and system, the method includes: obtaining the brain structure image data of subject brain;Based on brain structure image data, the feature parameter of characterizing brain tissue morphology is extracted;The characteristic parameter is handled by pre-training disease progression evaluation model, and the space-time progression trajectory of brain structure abnormality is inferred;Based on space-time progression trajectory, the disease subtype and disease progression stage to which the subject belongs are determined;Based on disease subtype and disease progression stage, evaluation information for characterizing the disease state of hepatic encephalopathy is generated.The space-time progression trajectory of brain structure abnormality is inferred based on cross-sectional image data, which overcomes the dependence on massive longitudinal tracking data, realizes the objective typing and staging of hepatic encephalopathy based on neurobiology, thereby effectively solving the technical problems of difficult to track disease evolution and individualized evaluation.

The present invention relates to the technical field of pharmaceuticals and specifically describes an application of a 5-hydroxytryptamine receptor 1A in preparing a drug for portal hypertension. The present invention achieved a significant decrease in portal venous pressure in model rats with cirrhotic portal hypertension by means of an HTR1A inhibitor WAY100635 administered at 1 mg / kg / day by intraperitoneal injection or alverine administered at 15 mg / kg / day by oral gavage. A 5-hydroxytryptamine receptor 1A antagonist can be used to prepare an experimental drug for the treatment of cirrhotic portal hypertension. Furthermore, the 5-hydroxytryptamine receptor 1A antagonist can also be used to prepare drugs for symptoms of portal hypertension syndrome, such as esophageal and fundal varices, rupture and bleeding, ascites, or hepatic encephalopathy. The present invention provides a novel treatment means to treat the manifestations of portal hypertension syndrome, such as esophageal and fundal varices, rupture and bleeding, ascites, or hepatic encephalopathy.

The invention discloses a portal vein stent shunt intraoperative blood flow proportion calculation method based on hemodynamics, and the method comprises the steps: obtaining target data which comprises target clinical measurement data and target image data after a target patient TIPS operation; calculating a target boundary condition based on the target data; constructing a target model, wherein the target model is a calculation model for calculating the blood mass flow rate based on geometric discretization and CFD simulation; and based on the target boundary condition and the target model, obtaining the blood proportion from the superior mesenteric vein and the spleen vein in the stent after the TIPS operation of the target patient. The blood proportion of the superior mesenteric vein and the splenic vein in the stent after the TIPS operation of the patient is calculated, and the difference of puncture from different branches of the portal vein in the TIPS operation is effectively judged, so that on the basis of effectively reducing the portal vein pressure, the occurrence of hepatic encephalopathy is reduced by optimizing the TIPS operation scheme.

The application relates to the biomedical application field of inorganic materials, and particularly relates to application of lanthanum carbonate in preparation of a medicine for treating hepatic encephalopathy. The application relates to application of lanthanum carbonate in preparation of a medicine for treating hepatic encephalopathy, wherein the medicine comprises lanthanum carbonate and pharmaceutically acceptable adjuvants, and the lanthanum carbonate comprises any one or more of lanthanum carbonate hydrate and basic lanthanum carbonate. The application is based on the fact that glutamine enzyme can reduce blood ammonia, and the hepatic encephalopathy is reversed by reducing blood ammonia and systemic inflammation, the liver function is recovered by regulating inflammation, thereby helping to cure the hepatic encephalopathy, and good treatment effect is shown, so that a new candidate medicine for clinically treating the hepatic encephalopathy is provided.

The invention relates to application of sevelamer. The medicine is particularly applied to treatment of hepatic encephalopathy. According to the method for orally taking the sevelamer compound preparation, the level of ammonia in blood can be remarkably reduced to the normal level, bile acid in the intestinal tract is combined, system inflammation is reduced, and therefore the sevelamer compound preparation is beneficial to curing hepatic encephalopathy, and no obvious side effect is found; the sevelamer oral administration method provided by the invention has a remarkable treatment effect on hepatic encephalopathy, a new candidate treatment medicine is expected to be brought to clinical hepatic encephalopathy, and meanwhile, the range of indications of sevelamer in clinical treatment is widened.

Overt hepatic encephalopathy is a serious complication of cirrhosis and affects lipid and lipoprotein metabolism. The present invention relates to a biomarker for the prognosis of hepatic encephalopathy. The biomarker includes one or more of high-density lipoprotein cholesterol, model for end-stage liver disease score, age, gender, upper gastrointestinal bleeding, spontaneous bacterial peritonitis, overt hepatic encephalopathy grade, ascites, aspartate aminotransferase, alanine aminotransferase, total bilirubin, serum albumin, total cholesterol, low-density lipoprotein cholesterol, serum creatinine, neutrophil-lymphocyte ratio, prothrombin time, and prothrombin activity level. Compared with patients with alcoholic hepatitis, liver disease, liver failure, etc. proposed in the prior art, due to the specificity of the target population, the biomarker proposed in this application can significantly improve the accuracy of the assessment of the prognosis of overt hepatic encephalopathy.

The invention discloses a hepatic encephalopathy recognition method, device and equipment based on metabolic ligation omics and a medium, and the method comprises the steps: S1, obtaining a metabolite data set; s2, high-difference connection screening is carried out; s3, screening key nodes; s4, drawing a reference mode; s5, individual connectivity omics quantification, and S6, mode recognition based on metabolic connectivity omics to solve the problems that in related technologies, due to the fact that the revealing strength of interaction between metabolites in a complex metabolic network is limited, understanding of network connectivity mode changes under different disease states is insufficient, metabolic connectivity of the individual level cannot be quantified, and the network connectivity is not quantified. And the objective property and the accuracy of the hepatic encephalopathy identification method are not enough.

The present disclosure relates to methods of treating or ameliorating hepatic encephalopathy (HE), including assessing the severity of HE in a patient suffering from HE, or the determining the presence or occurrence of an overt hepatic encephalopathy event. In particular, some aspects of the methods use a novel Hepatic Encephalopathy Staging Tool (HEST), which includes a set of criteria to categorize the HE into different stages and provide guidance on effective treatments based on the severity of the HE. Other aspects of the methods use an Overt Hepatic Encephalopathy Screening Tool (O-HEST) to determine whether an OHE event is occurring or has occurred and provide guidance on proper medical attention and change in treatment.

5′-O-Phenylacetyluridine effectively delivers both phenylacetate and uridine to a subject. It can be used to treat hepatic encephalopathy and genetic disorders of the hepatic nitrogen cycle.

The invention provides a deep reinforcement learning method and a screening system for testing occult hepatic encephalopathy. The method comprises the following steps: preprocessing basic feature data of a test object; a training rule of a training model is set, the model is a deep Q network used for the occult hepatic encephalopathy test, and the training rule comprises a test state representation rule, an action space for executing or terminating the test, a reward function and a confidence coefficient system; the deep Q network is trained according to the preprocessed clinical data and the training rule, a model obtained through training is used for testing the occult hepatic encephalopathy, an implementation technology for balancing the contradictory relation among reliability, high efficiency and accuracy of a test result is established, and the problems that an occult hepatic encephalopathy test method is long in time consumption and high in efficiency are solved. The patient adaptability is low, and the accuracy is insufficient under various noise factors.

The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin. The instant application also provides methods for determining if a subject has a neurological condition or hepatic encephalopathy by determining the critical flicker frequency and / or the venous ammonia level of the subject at two or more time points. The invention further provides methods for treating these subjects.

A compound of formula (I) or a salt thereof are provided:wherein R1, X and R3 are defined in the specification, useful in the treatment of disorders mediated by KMO such as acute pancreatitis, chronic kidney disease, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.

The present disclosure relates to methods and compositions for treating hepatic encephalopathy (HE). In aspects and embodiments, there is provided a method of treating a human subject having, or at risk of progressing to, HE comprising, administering a pharmaceutical composition comprising an effective amount of an H1 -antihistamine and / or mast cell stabilizer.

Provided are gene therapy vectors, such as adeno-associated virus (AAV), designed for treatment of mutations in the Eukaryotic Translation Initiation Factor 2B Subunit Epsilon (EIF2B5) gene. The EIF2B5 gene provides instructions for making one of five subunits of the elF2B protein, specifically the epsilon subunit of this protein. Such mutations are associated with a disease or disorder such as a leukoencephalopathy, a megalencephalic leukoencephalopathy, a leukodystrophy, a stroke, a migraine, epilepsy, multiple sclerosis (MS), Parkinson's disease (PD), Alzheimer's disease (AD), astrogliosis in aging, Huntington's Disease (HD), amyotrophic lateral sclerosis (ALS), Alexander disease, hepatic encephalopathy (HE), AicardinGoutieres syndrome, CLC-2-related disease, oculodentodigital dysplasia, and / or giant axonal neuropathy. Such leukoencephalopathies or leukodystrophies include, but are not limited to, Vanishing White Matter Disease (VWM). The disclosed gene therapy vectors provide a EIF2B5 cDNA to a subject in need which results in expression of a wild type or functional EIF2B5 protein. Also provided is a new promoter, designated gfa1405, which was designed to target astrocytes and neurons. Thus, compositions, nanoparticles, extracellular vesicles, exosomes, or vector comprising the gfa1405 promoter and methods of its use are also provided.

The application belongs to the technical field of biological medicine, and particularly relates to application of quinacrine, a pharmaceutically acceptable salt or a solvate thereof in preparation of a medicine for treating hepatic encephalopathy. The application finds that quinacrine can target and inhibit a PLA2G3 / cGAS-STING signal axis of microglia cells, and is used for treating hepatic encephalopathy. Specifically, quinacrine blocks a decrease of mitochondrial membrane phospholipid PE and activation of a cGAS-STING pathway induced by high ammonia by inhibiting PLA2G3 activity, thereby reducing release of proinflammatory factors (IL-1beta, IL-6, TNF-alpha, etc.), reversing abnormal activation of microglia cells to proinflammatory type, and inhibiting synaptic damage of neurons (restoring expression of PSD95 and SYN and morphology of dendritic spines), and finally improving cognitive function.

This utility model belongs to the field of experimental equipment technology, and discloses an ion monitoring device for a rabbit hepatic encephalopathy experimental model, including: an operating table with a monitoring system installed on it; the monitoring system includes a first base with a first fixing rod fixed in the center and two fixing clips on the first fixing rod; a tension transducer with its input end detachably connected to the fixing clips and a three-way valve detachably connected to the input end, with an endotracheal tube detachably connected to the three-way valve for monitoring respiratory rate; and a pressure transducer with its input end detachably connected to the fixing clip and a three-way valve detachably connected to the input end, with an arterial cannula detachably connected to the three-way valve for monitoring changes in arterial blood pressure, heart rate, and respiratory rate during the progression of rabbit hepatic encephalopathy (early, middle, progressive, and recovery phases), thereby increasing the scientific rigor and repeatability of the experimental operation.

The invention discloses a new application of S-methyl-5-thioadenosine, and the S-methyl-5-thioadenosine can be used as a hepatic encephalopathy biomarker. The invention relates to application of S-methyl-5-thioadenosine, a pharmaceutically acceptable salt thereof and / or a prodrug thereof as an active ingredient in preparation of drugs for preventing and / or treating hepatic encephalopathy, MHE and neuroinflammation and application of S-methyl-5-thioadenosine, a pharmaceutically acceptable salt thereof and / or a prodrug thereof as an active ingredient in preparation of drugs for preventing and / or treating hepatic encephalopathy, MHE and neuroinflammation. The invention also relates to application in medicines for improving cognition. Clinical data, animal experiments and cell model researches find that MTA can effectively relieve neuroinflammatory response of MHE patients, inhibit neuronal apoptosis and improve cognition, so that learning and memory ability is improved, and the application prospect is wide.

Use of an aromatic L-amino acid decarboxylase as a marker in a detection product for hepatic encephalopathy. It has been confirmed that the abundance of aromatic L-amino acid decarboxylase genes encoded by gut microbiota, as well as the product of aromatic L-amino acid decarboxylase, phenylethylamine, are increased in patients with hepatic encephalopathy; and compared with blood ammonia, hepatic encephalopathy can be more accurately diagnosed by means of phenylethylamine. This suggests that the occurrence of hepatic encephalopathy and the degree of progression of the disease can be quickly confirmed by detecting the patients' feces and serum, which increases the demand for clinical detection of hepatic encephalopathy. It has been confirmed that the baseline serum phenylethylamine level can effectively predict the incidence of hepatic encephalopathy at 3 months after TIPS surgery, which provides a detection means for early warning of hepatic encephalopathy.

This application discloses the use of an inhibitor of aromatic amino acid decarboxylase in the preparation of a drug for treating hepatic encephalopathy. This application targets aromatic amino acid decarboxylase and, through mouse experiments, demonstrates that inhibiting the activity of aromatic amino acid decarboxylase can reverse some symptoms of hepatic encephalopathy, suggesting that aromatic amino acid decarboxylase inhibitors have the potential to be used in the preparation of drugs for treating hepatic encephalopathy.

Methods for identifying biomarkers indicative of an increased risk for developing hepatic encephalopathy (HE) following transjugular intrahepatic portosystemic shunting (TIPS) are provided. Methods include determining whether the subject has a decreased level of metabolites following transjugular intrahepatic portosystemic shunting (TIPS), and / or determining a level of intrahepatic shunting in the subject. Methods for preventing and treating a subject having or at risk of having HE identified by the methods disclosed.

The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin.

The invention relates to the technical field of computer-aided diagnosis, and discloses a detection method and system for aided diagnosis of hepatic encephalopathy, and the system comprises a data collection module which is configured to collect comprehensive body data of a patient, and builds a disease influence data set according to the comprehensive body data; the data selection module is configured to output an influence value of each comprehensive body data in the illness influence data set on the hepatic encephalopathy based on the data importance model, and select the illness influence data set based on the influence value to obtain a core influence data set and a supplementary influence data set; the index calculation module is configured to obtain a core influence data set, divide regions according to a preset core partition value, and count the core data quantity of the comprehensive body data in each region; the HE index calculation module is configured to calculate an HE index according to the quantity of the core data and the quantity of the supplementary data; and a diagnosis early warning module. According to the invention, early, accurate and objective diagnosis of hepatic encephalopathy is realized.

A system for screening hepatic encephalopathy (HE) based on critical flicker fusion frequency (CFFF) detection using visual perception thresholds. The system comprises a frequency setter module that generates a controlled sequence of flickering light signals, an internal oscillator for precise timing, and a frequency tracker module that adjusts the flicker rate based on patient feedback. A frequency re-setter module ensures visual memory effects are minimized by introducing a non-flickering baseline between steps. The system includes a light controller that emits spectrally filtered, intensity-calibrated light optimized for retinal sensitivity. A patient feedback input module records flicker perception responses, while a recording module logs test parameters and outcomes. A secure communication module transmits this data to a remote interface for clinical evaluation. The system dynamically adapts to patient input, enhancing accuracy in determining CFFF, a validated biomarker for minimal HE, thereby enabling early, objective, and non- invasive screening of cognitive dysfunction.

Provided is a Bifidobacterium lactis. The Bifidobacterium lactis is Bifidobacterium animalis subsp. lactis BL-11, and the preservation number of the Bifidobacterium animalis subsp. lactis BL-11 is CGMCC No. 20847. The provided Bifidobacterium animalis subsp. lactis can improve intestine metabolism disorder and normalize the composition of intestine microbiome so as to improve height, suppresses obesity, promote infant and youth physical development and mental development, and prevent and treat mental disorders, said mental disorders including anxiety, depression, attention-deficit / hyperactivity disorder, autism, schizophrenia, hepatic encephalopathy, anorexia, Tourette syndrome, and Asperger syndrome.

The present application discloses the use of aromatic amino acid decarboxylase as a biomarker in a detection product for hepatic encephalopathy. It is confirmed that the abundance of the aromatic amino acid decarboxylase gene encoded by the intestinal flora and the aromatic amino acid decarboxylase product phenethylamine increase in patients with hepatic encephalopathy. Moreover, compared with blood ammonia, phenethylamine can more accurately diagnose hepatic encephalopathy, indicating that it is possible to quickly confirm whether hepatic encephalopathy has occurred and the degree of disease development by detecting the feces and serum of patients, thus meeting the clinical detection needs of hepatic encephalopathy. The present application also confirms that the baseline serum phenethylamine level can effectively predict the incidence of hepatic encephalopathy three months after Tips surgery, providing a detection means for early warning of hepatic encephalopathy.